Catalyst Wire Dossier Catalyst Wire Dossier

Relebactam + Imipenem/Cilastatin

relebactam · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Relebactam + Imipenem/Cilastatin, covering 2019-06-10 to 2019-06-10. Get the full timeline:

Most recent: Clinical Trial Update: Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004) [Phase 2]

See pricing